Optimise

Should I take low-dose aspirin? A decision aid trial

Recently new evidence has emerged for daily low-dose aspirin in cancer prevention. The challenge is weighing these up and identifying patients for whom the benefit-risk ratio is most favourable.  This study aims to develop the ‘Optimise’ model decision tool combining individual patient benefit and harm estimates for daily low-dose aspirin; assess the effect of the tool on self-reported aspirin-taking behaviour; and assess the short-term impact of the intervention on CVD, cancer and bleeding outcomes using linked health administrative data.

Current status:

Funded, in development

For more information contact:

Chief Investigator Prof Lyndal Trevena, Sydney Medical School, University of Sydney (lyndal.trevena@sydney.edu.au)